Drug Repurposing for Emerging Infectious Diseases and Cancer
- Publisher's listprice EUR 213.99
-
88 752 Ft (84 526 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 17 750 Ft off)
- Discounted price 71 002 Ft (67 621 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
88 752 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 1st ed. 2023
- Publisher Springer Nature Singapore
- Date of Publication 8 February 2024
- Number of Volumes 1 pieces, Book
- ISBN 9789811954016
- Binding Paperback
- See also 9789811953989
- No. of pages654 pages
- Size 235x155 mm
- Weight 1194 g
- Language English
- Illustrations XXI, 654 p. 1 illus. Illustrations, black & white 527
Categories
Long description:
This book presents drug repurposing strategies to combat infectious diseases and cancer. It discusses key experimental and in silico approaches for modern drug repositioning, including signature matching, molecular docking, genome-wide associated studies, and network-based approaches aided by artificial intelligence. Further, the book presents various computational and experimental strategies for better understanding disease mechanisms and identify repurposed drug candidates for personalized pharmacotherapy. It also explores the databases for drug repositioning, summarizes the approaches taken for drug repositioning, and highlights and compares their characteristics and challenges. Towards the end, the book discusses challenges and limitations encountered in computational drug repositioning.
MoreTable of Contents:
Chapter 1. Drug repurposing: an advance way to traditional drug discovery.- Chapter 2. Drug polypharmacology towards drug repurposing.- Chapter 3. Pharmacovigilance based drug repurposing.- Chapter 4. In silico analysis of cellular interactors of pqbp1 for potential drug repurposing.- Chapter 5. Drug repurposing opportunities in cancer.- Chapter 6. Repurposing of flavonoids as promising phytochemicals for the treatment of lung carcinoma.- Chapter 7. Targeted therapies used in the treatment of non-small cell lung cancer: an overvie.- Chapter 8. Targeting the ubiquitin machinery for cancer therapeutics.- Chapter 9. Repurposing of serotonin pathway influencing drugs for potential cancer therapy and antimicrobial functions.- Chapter 10. Drug repurposing for hematological malignancies.- Chapter 11. Drug repurposing for ent and head and neck infectious and oncologic diseases: current practices and future possibilities.- Chapter 12. Repurposing of immun-modulators for the treatment of cancer with qsar approaches.- Chapter 13. Reverse translational approach in repurposing of drugs for anticancer therapy.- Chapter 14. Therapeutic targeting of antineoplastic drugs in alzheimer’s disease: discovered in repurposed agents.- Chapter 15. Repurposing of drugs for the treatment of microbial diseases.- Chapter 16. Repurposing anti-inflammatory agents in the potential treatment of sars-cov-2 infection.- Chapter 17. Repurposing drugs for viruses and cancer: a novel drug repositioning strategy for covid-19.- Chapter 18. Repurposing of serotonin pathway influencing drugs for potential cancer therapy and antimicrobial functions.- Chapter 19. Drug repurposing for covid-19 therapy: pipeline, current status and challenges.- chapter 20. Deoxy-d-glucose - a repurposed drug for covid-19 treatment.- Chapter 21. Repurposing methylene blue for the management of covid-19: prospects, paradox and perspective.- Chapter 22. Drug repurposing in covid-19 and cancer: how far have we come?.- Chapter 23.Repurposing of doxycycline to attenuate influenza virus pathogenesis via inhibition of matrix metalloproteinases in neutrophils.- Chapter 24. Therapeutic repurposing approach: new opportunity for developing drugs against covid‐19.- chapter 25. Repurposing drugs for viruses and cancer: a novel drug repositioning strategy for covid-19.- Chapter 26. Repurposing of therapeutic approaches for the treatment of vitiligo.- Chapter 27. Emerging infections and their management.- Chapter 28. Repurposing of minocycline, a tetracycline antibiotic, for neurodegenerative disorders.
More
Frommer's? Mexico 2005: A Companion to Shakespeare's Works
7 161 HUF
6 445 HUF
